NASDAQ:GRFSGRIFOLS S A/S Stock Price, Forecast & News

$19.75

-0.37 (-1.84 %)

(As of 06/3/2020 03:50 PM ET)

Add

Compare

Today's Range

$19.68

Now: $19.75▼

$19.99

50-Day Range

$18.76

MA: $20.07▼

$21.45

52-Week Range

$13.40

Now: $19.75▼

$25.73

Volume47,558 shs

Average Volume696,754 shs

Market Capitalization$13.58 billion

P/E Ratio17.63

Dividend Yield1.72%

Beta0.83

Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Beat the Market (BTM) Rank^™

2.3 Analyst's Opinion

Consensus Rating
GRIFOLS S A/S has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.50, GRIFOLS S A/S has a potential upside of 13.9% from its current price of $19.76.
Amount of Analyst Coverage
GRIFOLS S A/S has only been the subject of 4 research reports in the past 90 days.

2.1 Community Rank

Outperform Votes
GRIFOLS S A/S has received 310 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
GRIFOLS S A/S has received 444 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
GRIFOLS S A/S has received 58.89% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about GRIFOLS S A/S and other stocks. Vote “Outperform” if you believe GRFS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GRFS will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Leadership
GRIFOLS S A/S is a leading dividend payer. It pays a dividend yield of 1.72%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
GRIFOLS S A/S has only been increasing its dividend for 2 years.
Dividend Coverage
The dividend payout ratio of GRIFOLS S A/S is 29.06 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, GRIFOLS S A/S will have a dividend payout ratio of 22.52 % next year. This indicates that GRIFOLS S A/S will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GRIFOLS S A/S insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 17.88% of the stock of GRIFOLS S A/S is held by institutions.

1.9 Earnings and Valuation

Earnings Growth
Earnings for GRIFOLS S A/S are expected to grow by 11.03% in the coming year, from $1.36 to $1.51 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GRIFOLS S A/S is 17.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.08.
Price to Earnings Ratio vs. Sector
The P/E ratio of GRIFOLS S A/S is 17.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.36.
Price to Earnings Growth Ratio
GRIFOLS S A/S has a PEG Ratio of 1.04. PEG Ratios around 1 indicate that a company is correctly valued.
Price to Book Value per Share Ratio
GRIFOLS S A/S has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.92 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:GRFS

Previous Symbol

CUSIPN/A

CIK1438569

Webwww.grifols.com

Phone34-93-571-0000

Debt

Debt-to-Equity Ratio0.95

Current Ratio2.75

Quick Ratio0.90

Price-To-Earnings

Trailing P/E Ratio17.63

Forward P/E Ratio14.52

P/E Growth1.04

Sales & Book Value

Annual Sales$5.71 billion

Price / Sales2.38

Cash Flow$1.67 per share

Price / Cash Flow11.84

Book Value$11.15 per share

Price / Book1.77

Profitability

EPS (Most Recent Fiscal Year)$1.17

Net Income$700.16 million

Net Margins13.31%

Return on Equity11.92%

Return on Assets4.91%

Miscellaneous

Employees22,244

Outstanding Shares687,550,000

Market Cap$13.58 billion

Next Earnings Date7/29/2020 (Estimated)

OptionableOptionable

Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions

How has GRIFOLS S A/S's stock been impacted by COVID-19 (Coronavirus)?

GRIFOLS S A/S's stock was trading at $20.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GRFS stock has decreased by 2.9% and is now trading at $19.76. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of GRIFOLS S A/S?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GRIFOLS S A/S.

When is GRIFOLS S A/S's next earnings date?

GRIFOLS S A/S is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for GRIFOLS S A/S.

How were GRIFOLS S A/S's earnings last quarter?

GRIFOLS S A/S (NASDAQ:GRFS) issued its earnings results on Tuesday, April, 21st. The biotechnology company reported $0.25 EPS for the quarter, beating the Zacks' consensus estimate of $0.24 by $0.01. The biotechnology company had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.40 billion. GRIFOLS S A/S had a net margin of 13.31% and a return on equity of 11.92%. View GRIFOLS S A/S's earnings history.

How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S?

GRIFOLS S A/S announced a semi-annual dividend on Thursday, October 31st. Stockholders of record on Tuesday, December 3rd will be paid a dividend of $0.169 per share on Wednesday, December 11th. This represents a yield of 1.3%. The ex-dividend date is Monday, December 2nd. This is a boost from GRIFOLS S A/S's previous semi-annual dividend of $0.15. View GRIFOLS S A/S's dividend history.

When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work?

GRIFOLS S A/S's stock split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were distributed to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

What price target have analysts set for GRFS?

8 brokers have issued 12 month price targets for GRIFOLS S A/S's shares. Their forecasts range from $22.50 to $22.50. On average, they expect GRIFOLS S A/S's share price to reach $22.50 in the next twelve months. This suggests a possible upside of 13.9% from the stock's current price. View analysts' price targets for GRIFOLS S A/S.

Has GRIFOLS S A/S been receiving favorable news coverage?

Media stories about GRFS stock have trended very negative recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. GRIFOLS S A/S earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutGRIFOLS S A/S.

Are investors shorting GRIFOLS S A/S?

GRIFOLS S A/S saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,960,000 shares, an increase of 27.3% from the April 15th total of 1,540,000 shares. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is currently 1.7 days. Currently, 0.8% of the shares of the stock are short sold. View GRIFOLS S A/S's Current Options Chain.

Who are some of GRIFOLS S A/S's key competitors?

Some companies that are related to GRIFOLS S A/S include ASTELLAS PHARMA/ADR (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TKPYY), UCB (UCBJF), Genmab A/S (GMAB), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Beigene (BGNE), Sarepta Therapeutics (SRPT) and Catalent (CTLT). View all competitors.

What other stocks do shareholders of GRIFOLS S A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Abbott Laboratories (ABT), Alibaba Group (BABA), Pfizer (PFE), AbbVie (ABBV), Allergan (AGN), Nektar Therapeutics (NKTR) and Johnson & Johnson (JNJ).

Who are GRIFOLS S A/S's key executives?

GRIFOLS S A/S's management team includes the following people:

Mr. Raimon Grifols Roura, Co-CEO & Exec. Director (Age 55)
Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 63)
Mr. Víctor Grífols Deu, Co-CEO & Exec. Director (Age 42)
Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 61)
Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs

What is GRIFOLS S A/S's stock symbol?

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

Who are GRIFOLS S A/S's major shareholders?

GRIFOLS S A/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include AKO Capital LLP (1.93%), Pictet Asset Management Ltd. (1.14%), TPG Group Holdings SBS Advisors Inc. (0.67%), Capital Research Global Investors (0.63%), Janus Henderson Group PLC (0.59%) and Baillie Gifford & Co. (0.46%).

Which major investors are selling GRIFOLS S A/S stock?

GRFS stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., UBS Group AG, Morgan Stanley, Morgan Stanley, Two Sigma Investments LP, Bank of New York Mellon Corp, Deutsche Bank AG, and Van ECK Associates Corp.

Which major investors are buying GRIFOLS S A/S stock?

GRFS stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., TPG Group Holdings SBS Advisors Inc., Janus Henderson Group PLC, Impax Asset Management Group plc, AKO Capital LLP, Pelham Capital Ltd., Whitebox Advisors LLC, and Soros Fund Management LLC.

How do I buy shares of GRIFOLS S A/S?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GRIFOLS S A/S's stock price today?

One share of GRFS stock can currently be purchased for approximately $19.76.

How big of a company is GRIFOLS S A/S?

GRIFOLS S A/S has a market capitalization of $13.59 billion and generates $5.71 billion in revenue each year. The biotechnology company earns $700.16 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 22,244 workers across the globe.

What is GRIFOLS S A/S's official website?

The official website for GRIFOLS S A/S is www.grifols.com.

How can I contact GRIFOLS S A/S?

GRIFOLS S A/S's mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-0000 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff